In a new paper released Oct. 24 in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.
All contemporary, as well as NextGen and Third Generation sequencing methodologies are dependent on the generation of DNA fragments from initial MegaBase long chromosomal DNA molecules. General requirements are that such fragments have to be random and of similar size.